Nexthera Capital’s Ovid Therapeutics OVID Stock Holding History

Nexthera Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30,543	Closed	-$320K	–	43
2017 Q2	$320K	Buy	+30,543	New	+$399K	0.14%	39

Other funds holding OVID

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Nexthera Capital's OVID Position: Q3 2017 in Review

Nexthera Capital sold out of Ovid Therapeutics (OVID) in Q3 2017, closing a stake of 30,543 shares — an estimated $320K sold.

Nexthera Capital first reported a position in OVID in Q2 2017 and held it in 1 quarter. The position peaked at $320K in Q2 2017. 42 funds tracked by Wall St. Rank hold OVID as of Q3 2017.

Nexthera Capital reported no remaining Ovid Therapeutics position as of Q3 2017 after selling out during the quarter.
Nexthera Capital sold 30,543 Ovid Therapeutics shares in Q3 2017, an estimated $320K.
Nexthera Capital first reported a position in Ovid Therapeutics in Q2 2017 and held it in 1 quarter.
Nexthera Capital's Ovid Therapeutics position peaked at $320K in Q2 2017.
42 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2017.

Based on Nexthera Capital's 13F filing for Q3 2017, filed 14 Nov 2017.